Updates are available Correction dated 2026-06-16
Click to view Correction: https://doi.org/10.1007/s00432-026-06528-3
-
Authors
Li, Sijian
Xian, Bingna
Cui, Lanyue
Wu, Linyu
Fang, Cheng
Yang, Fan
Li, Jundong
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 82403265 and 82404078)
Guangdong Basic and Applied Basic Research Foundation (No. 2023A1515110701)
- License Information
-
More Information
Article History
Received: 28 January 2026
Accepted: 10 March 2026
First Online: 27 March 2026
Change Date: 3 June 2026
Change Type: Update
Change Details: In this article, two instances of ‘bevacizumab (10 mg/m<sup>2</sup>)’ need to be corrected to ‘bevacizumab 10 mg/kg’. These errors appear in the Abstract and Materials and Methods (Study design and participants) section.
Change Date: 16 June 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00432-026-06528-3
Declarations
:
: This retrospective study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center (reference number: B2025-590-01, date of approval: August 18th, 2025), and all methods were carried out following the Declaration of Helsinki. Written informed consent to participate in the study was waived by the ethics committee due to the retrospective nature of the study.
: The authors declare that they have no conflict of interest.
